Sarepta Therapeutics Inc (NASDAQ: SRPT)

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
To analyze Sarepta’s stock for potential trading opportunities, please take a look at the 1-year chart of SRPT (Sarepta Therapeutics, Inc.) below with my added notations:

SRPT has been trading between $30 and $35 for almost two months. Those two price levels are not new to the stock. Both $30 and $35 have been prior supports and resistances throughout the last year. SRPT’s next bigger move should be dictated based on which of those two levels break first.

The Tale of the Tape: SRPT is trading between $30 and $35. A long trade could be made on a pullback down to $30 or on a break through $35. Short trades could be made if the stock breaks below $30 or approaches $35 again.
Please share this article